TIA
MCID: TRN015
MIFTS: 59

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 56 15 74
Transient Ischemic Attack 12 55 56 6 44 15 17 74
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Transient Ischemic Attacks 12
Ischemic Attack, Transient 45
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
MeSH 45 D002546
NCIt 51 C50781
SNOMED-CT 69 38609002
ICD10 34 G45.9

Summaries for Transient Cerebral Ischemia

MedlinePlus : 44 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Neuroscience. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes.

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 55 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 77 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.3 CASP3 HSPA1A HSPA4 MAP2
2 stroke, ischemic 30.9 APOH CASP3 HSPA4 MAP2 NOTCH3
3 cytomegalovirus infection 29.8 CASP3 CCL2 IL1B
4 carotid artery occlusion 29.1 APOH HSPA1A MAP2
5 mini stroke 11.8
6 peripheral vascular disease 11.6
7 moyamoya disease 1 11.5
8 sneddon syndrome 11.4
9 moyamoya disease 2 11.4
10 moyamoya disease 6 with or without achalasia 11.4
11 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.3
12 buerger disease 11.3
13 telangiectasia, hereditary hemorrhagic, type 4 11.3
14 moyamoya disease 5 11.3
15 vertebrobasilar insufficiency 11.3
16 pulmonary arterio-veinous fistula 11.3
17 paresthesia 11.3
18 carotid artery disease 11.2
19 aganglionosis, total intestinal 11.1
20 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.1
21 carotid stenosis 10.4
22 arteries, anomalies of 10.4
23 thrombosis 10.4
24 diabetes mellitus 10.4
25 dementia 10.3
26 atrial fibrillation 10.3
27 coronary artery anomaly 10.2
28 rere-related disorders 10.2
29 fabry disease 10.1
30 acute myocardial infarction 10.1
31 congestive heart failure 10.1
32 atrial heart septal defect 10.1
33 pulmonary embolism 10.1
34 purulent labyrinthitis 10.1 CCL2 IL1B
35 hyperglycemia 10.1
36 alcohol abuse 10.1
37 glucose intolerance 10.1
38 thrombophilia 10.1
39 herpes zoster 10.1
40 retinitis pigmentosa 73 10.0 CCL2 IL1B
41 apnea, obstructive sleep 10.0
42 multiple sclerosis 10.0
43 rheumatoid arthritis 10.0
44 thrombophilia due to thrombin defect 10.0
45 takayasu arteritis 10.0
46 acute promyelocytic leukemia 10.0
47 deficiency anemia 10.0
48 arthritis 10.0
49 chronic kidney failure 10.0
50 hereditary hemorrhagic telangiectasia 10.0

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 89)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Labyrinthitis Left Bundle Branch Hemiblock

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, tremor, angina pectoris, edema, back pain, amaurosis fugax, pain, chest pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
3
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
4
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
5
Losartan Approved Phase 4 114798-26-4 3961
6
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
9
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
10
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
11
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 9052 54676537
12
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
13
Apixaban Approved Phase 4,Phase 3,Not Applicable 503612-47-3 10182969
14
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 134523-00-5 60823
15
Amlodipine Approved Phase 4,Phase 3,Not Applicable 88150-42-9 2162
16
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 9908 54680692
17
tannic acid Approved Phase 4,Phase 3,Phase 2 1401-55-4
18
Amiodarone Approved, Investigational Phase 4,Not Applicable 1951-25-3 2157
19
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
20
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
21
Dobutamine Approved Phase 4,Phase 3 34368-04-2 36811
22
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
23
Cilostazol Approved, Investigational Phase 4,Phase 2,Not Applicable 73963-72-1 2754
24
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
25
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6
26
Tranexamic Acid Approved Phase 4,Not Applicable 1197-18-8 5526
27
Febuxostat Approved Phase 4,Not Applicable 144060-53-7 134018
28
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
29
Edoxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 480449-70-5
30
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
31
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
32
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
33
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
34
Dipyridamole Approved Phase 4,Phase 3,Not Applicable 58-32-2 3108
35
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
36
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
37
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
38
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
39
Everolimus Approved Phase 4,Not Applicable 159351-69-6 6442177 70789204
40
Sirolimus Approved, Investigational Phase 4,Phase 3,Not Applicable 53123-88-9 46835353 6436030 5284616
41
Miconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 22916-47-8 4189
42
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
43
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
44
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
45
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
46
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
47
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
48
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
49
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
50
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2 84-80-0

Interventional clinical trials:

(show top 50) (show all 750)
# Name Status NCT ID Phase Drugs
1 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
2 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
3 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
4 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
5 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Unknown status NCT02594800 Phase 4 Rosuvastatin
6 Treatment of Reperfusion Event by Vitamin C Infusion Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
7 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
8 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
9 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
10 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
11 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
12 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
13 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
14 Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
15 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
16 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
17 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
18 Hypertension Control Based on Home Blood Pressure Unknown status NCT00198562 Phase 4 Amlodipine, Losartan
19 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
20 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
21 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
22 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
23 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
24 Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI Completed NCT02640794 Phase 4 Clopidogrel;Aspirin
25 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
26 Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
27 Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial Completed NCT01559298 Phase 4 Aspirin (80 mg/d) + clopidogrel (75 mg/d);Aspirin
28 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Completed NCT00562588 Phase 4 Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg);ASA 100 mg qd
29 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed NCT02348723 Phase 4 Warfarin;Dabigatran Etexilate 150mg
30 Metformin-Dipyridamole Interaction Trial Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
31 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
32 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
33 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
34 NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Completed NCT00964392 Phase 4
35 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement Completed NCT00293241 Phase 4
36 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
37 Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery Completed NCT01146301 Phase 4 Clopidogrel
38 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) Completed NCT00234065 Phase 4 Cilostazol;Aspirin
39 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
40 Carvedilol Post-intervention Long-term Administration in Large-scale Trial Completed NCT01155635 Phase 4 Carvedilol;No Carvedilol
41 Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis Completed NCT00257283 Phase 4 Omega-3-acid ethyl esters 90
42 Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II) Completed NCT00289042 Phase 4 Enoxaparin
43 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed NCT00262119 Phase 4
44 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4 Olmesartan medoxomil;Calcium channel blockers (amlodipine, azelnidipine)
45 Cilostazol Stroke Prevention Study for Antiplatelet Combination Completed NCT01995370 Phase 4 aspirin;clopidogrel;cilostazol
46 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
47 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
48 Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan Completed NCT01069302 Phase 4 Clopidogrel;Clopidogrel;Clopidogrel;Clopidogrel
49 Tranexamic Acid Dosing for Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
50 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ Completed NCT00377611 Phase 4

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

42
Brain, Eye, Testes, Kidney, Spinal Cord, Retina, Endothelial

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 1936)
# Title Authors Year
1
Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation. ( 30691339 )
2019
2
A Combination of Ulinastatin and Xuebijing Amplifies Neuroprotection after Transient Cerebral Ischemia via Attenuating Apoptosis Signal Pathways in Hippocampus. ( 30727870 )
2019
3
Dissecting functional phenotypes of microglia and macrophages in the rat brain after transient cerebral ischemia. ( 30485549 )
2019
4
Headaches Attributed to Ischemic Stroke and Transient Ischemic Attack. ( 30667047 )
2019
5
Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting With Transient Ischemic Attack. ( 30685057 )
2019
6
Efficacy of High-intensity Statin Use for Transient Ischemic Attack Patients with Positive Diffusion-weighted Imaging. ( 30718523 )
2019
7
Transient ischemic attack: Incidence and early risk of stroke in northern Portugal from 1998-2000 to 2009-2011. ( 30734663 )
2019
8
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( 30742211 )
2019
9
The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. ( 30747613 )
2019
10
Ultrasound Evaluation of Transient Ischemic Attack Caused by Styloid Process Elongation: A Case Report. ( 30761067 )
2019
11
The Local Brain Abnormalities in Patients With Transient Ischemic Attack: A Resting-State fMRI Study. ( 30804735 )
2019
12
Transient Ischemic Attack in a High-Risk Cardiovascular Patient with Renal Dysfunction after Treatment with Rivaroxaban and Clopidogrel: A Case Report. ( 30828094 )
2019
13
Comparison of administration of clopidogrel with aspirin versus aspirin alone in prevention of secondary stroke after transient ischemic attack. ( 30830517 )
2019
14
Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. ( 30837927 )
2019
15
Comparative efficacy and safety of multiple antiplatelet therapies for secondary prevention of ischemic stroke or transient ischemic attack: A network meta-analysis. ( 30849580 )
2019
16
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( 30852971 )
2019
17
Corneal nerve and endothelial cell damage in patients with transient ischemic attack and minor ischemic stroke. ( 30875374 )
2019
18
Global Brain Perfusion and the Risk of Transient Ischemic Attack and Ischemic Stroke: The Rotterdam Study. ( 30905232 )
2019
19
Imaging Diagnosis of Transient Ischemic Attack in Clinic and Traditional Chinese Medicine. ( 30906774 )
2019
20
Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. ( 30914063 )
2019
21
The Impact of Transient Ischemic Attack (TIA) on Brain and Behavior. ( 30914931 )
2019
22
Non-invasive evaluation of cerebral perfusion in patients with transient ischemic attack: an fMRI study. ( 30446964 )
2019
23
Stroke risk after transient ischemic attack in a Norwegian prospective cohort. ( 30606138 )
2019
24
Health-Related Quality of Life and Fatigue After Transient Ischemic Attack and Minor Stroke. ( 30612638 )
2019
25
A systematic review of the risk of motor vehicle collision after stroke or transient ischemic attack. ( 30614401 )
2019
26
Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack. ( 30626286 )
2019
27
Pre-existing White Matter Hyperintensity Lesion Burden and Diagnostic Certainty of Transient Ischemic Attack. ( 30630754 )
2019
28
Functional and emotional outcomes after transient ischemic attack: A 12-month prospective controlled cohort study. ( 30632952 )
2019
29
Contemporary prognosis of transient ischemic attack patients: A systematic review and meta-analysis. ( 30632953 )
2019
30
Deep Learning Natural Language Processing Successfully Predicts the Cerebrovascular Cause of Transient Ischemic Attack-Like Presentations. ( 30653397 )
2019
31
Transient Ischemic Attack and Carotid Web. ( 30655258 )
2019
32
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( 29084736 )
2018
33
Ischemic stroke/transient ischemic attack events and carotid artery disease in the absence of or with minimal coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis. ( 29852401 )
2018
34
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
35
Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. ( 29880551 )
2018
36
Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of Nrf2 expression in ovariectomized rats. ( 29688134 )
2018
37
Effects of Scrambling trumpet Creeper flavone on transient cerebral ischemia model (TIA) in rats. ( 29686511 )
2018
38
Upregulation of heme oxygenase-1 protected against brain damage induced by transient cerebral ischemia-reperfusion injury in rats. ( 29805479 )
2018
39
Neuroprotection of ulinastatin on transient cerebral ischemia via antioxidative mechanisms. ( 29685007 )
2018
40
Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis. ( 29335335 )
2018
41
EAAC1 gene deletion reduces adult hippocampal neurogenesis after transient cerebral ischemia. ( 29720605 )
2018
42
Correction to: Inactivation of NSF ATPase Leads to Cathepsin B Release After Transient Cerebral Ischemia. ( 29796935 )
2018
43
Transient ischemic attack characterized by external strabismus of the left eye: A case report. ( 29901646 )
2018
44
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia. ( 29896413 )
2018
45
Combined Treatment With Dichloroacetic Acid and Pyruvate Reduces Hippocampal Neuronal Death After Transient Cerebral Ischemia. ( 29593636 )
2018
46
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 29399074 )
2018
47
Tumor necrosis factor receptor 2 is required for ischemic preconditioning-mediated neuroprotection in the hippocampus following a subsequent longer transient cerebral ischemia. ( 29777731 )
2018
48
Treatment with Uric Acid Reduces Infarct and Improves Neurologic Function in Female Mice After Transient Cerebral Ischemia. ( 29398531 )
2018
49
Ulinastatin alleviates neurological deficiencies evoked by transient cerebral ischemia via improving autophagy, Nrf-2-ARE and apoptosis signals in hippocampus. ( 29750875 )
2018
50
Long-term treadmill exercise improves memory impairment through restoration of decreased synaptic adhesion molecule 1/2/3 induced by transient cerebral ischemia in the aged gerbil hippocampus. ( 29341891 )
2018

Variations for Transient Cerebral Ischemia

ClinVar genetic disease variations for Transient Cerebral Ischemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh38 Chromosome 19, 15192182: 15192182
2 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh37 Chromosome 19, 15302993: 15302993
3 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic rs1555728965 GRCh37 Chromosome 19, 15299088: 15299088
4 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic rs1555728965 GRCh38 Chromosome 19, 15188277: 15188277

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

Pathways related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 BAD CCL2 IL1B PTK2B
2 12.35 GRIN2A MAP2 NOTCH3 SLC1A1
3
Show member pathways
11.96 CCL2 IL1B KMO KYNU
4
Show member pathways
11.92 CASP3 CCL2 MAP2 PTK2B
5
Show member pathways
11.89 CASP3 CCL2 IL1B LCN2
6 11.75 CASP3 CCL2 IL1B
7
Show member pathways
11.73 BAD CASP3 HSPA1A IL1B
8 11.71 CCL2 IL1B LCN2
9 11.67 CASP3 CCL2 IL1B
10 11.58 CASP3 CCL2 IL1B
11
Show member pathways
10.98 BAD CASP3 GRIN2A SLC1A1
12 10.87 CASP3 HSPA1A IL1B
13 10.64 CCL2 IL1B

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 BAD CASP3 GCKR HSPA1A HSPA4 IL1B
2 NMDA selective glutamate receptor complex GO:0017146 8.96 GRIN2A PTK2B

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.78 CCL2 IL1B KMO LCN2
2 cellular response to interleukin-1 GO:0071347 9.76 CCL2 KMO LCN2
3 response to glucose GO:0009749 9.73 BAD CASP3 PTK2B
4 MAPK cascade GO:0000165 9.72 CCL2 IL1B PTK2B
5 cellular response to organic cyclic compound GO:0071407 9.71 CASP3 CCL2 IL1B
6 response to hydrogen peroxide GO:0042542 9.69 BAD CASP3 PTK2B
7 cytokine-mediated signaling pathway GO:0019221 9.65 BAD CASP3 CCL2 IL1B LCN2
8 chaperone-mediated protein complex assembly GO:0051131 9.63 HSPA1A HSPA4
9 long-term synaptic potentiation GO:0060291 9.63 DRD1 GRIN2A PTK2B
10 long-term synaptic depression GO:0060292 9.62 DRD1 PTK2B
11 response to estradiol GO:0032355 9.62 BAD CASP3
12 dopamine metabolic process GO:0042417 9.61 DRD1 GRIN2A
13 activation of cysteine-type endopeptidase activity GO:0097202 9.61 BAD GRIN2A
14 NAD biosynthetic process GO:0009435 9.6 KMO KYNU
15 pyridine nucleotide biosynthetic process GO:0019363 9.59 KMO KYNU
16 memory GO:0007613 9.58 DRD1 GRIN2A
17 cellular response to organic substance GO:0071310 9.58 CASP3 IL1B MAP2
18 tryptophan catabolic process GO:0006569 9.57 KMO KYNU
19 response to glucocorticoid GO:0051384 9.52 BAD CASP3
20 positive regulation of glucokinase activity GO:0033133 9.49 BAD GCKR
21 'de novo' NAD biosynthetic process from tryptophan GO:0034354 9.43 KMO KYNU
22 anthranilate metabolic process GO:0043420 9.37 KMO KYNU
23 response to ethanol GO:0045471 9.33 BAD GRIN2A PTK2B
24 quinolinate biosynthetic process GO:0019805 9.32 KMO KYNU
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.26 BAD CASP3 IL1B LCN2
26 response to drug GO:0042493 9.1 BAD CASP3 DRD1 GRIN2A LCN2 PTK2B

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 8.96 BAD CASP3
2 NMDA glutamate receptor activity GO:0004972 8.62 GRIN2A PTK2B

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....